Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Efavirenz (EFV)
Efavirenz · 3 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| 1 | ACTIVE_COMPARATOR | efavirenz |
| 2 | EXPERIMENTAL | raltegravir 400 mg |
| 3 | EXPERIMENTAL | raltegravir 800 mg |
| Name | Type | Description |
|---|---|---|
| efavirenz | DRUG | tenofovir 245 mg / lamivudine 300 mg / efavirenz 600 mg |
| raltegravir | DRUG | tenofovir 245 mg / lamivudine 300 mg / raltegravir 400 mg |
| Adefovir dipivoxil | DRUG | - |
| Lamivudine | DRUG | - |
| Didanosine | DRUG | - |
| Abacavir sulfate | DRUG | - |
| Amprenavir | DRUG | - |
Inclusion Criteria: * Adult patients (at least 18 years old) * Plasma HIV RNA \> 1000 copies/ml * HIV-1-infection confirmed by ELISA and Western blot or Immunofluorescence * ART naïve patients or * ART for less than 3 months and more than 6 months ago ; an HIV resistance genotype at baseline showin...
Top 19 of 30 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Pfizer Inc. | PFE | 7 | PHASE3 | VLA15, Prevenar 20, 13vPnC, ATM-AVI, PG4 |
| Sanofi SA Sponsored ADR | SNY | 1 | PHASE3 | PCV21 |
| GSK plc Sponsored ADR | GSK | 4 | PHASE2 | Penmenvy, iNTS-TCV, Strep A vaccine, Pan-Salmonella vaccine |
| Grifols, S.A. Sponsored ADR Class B | GRFS | 1 | PHASE3 | Xembify |
| CorMedix Inc. | CRMD | 1 | PHASE3 | DefenCath |
| Sinovac Biotech Ltd. | SVA | 4 | PHASE3 | Sinovac PCV24, Group ACYW135X Meningococcal Conjugate Vaccine, Group ACYW135 Meningococcal Conjugate Vaccine |
| Novartis AG Sponsored ADR | NVS | 2 | PHASE2 | EDI048 |
| Innoviva, Inc. | INVA | 3 | PHASE2 | Eravacycline, Sulbactam-durlobactam |
| BiomX Inc. | PHGE | 1 | PHASE2 | BX004 |
| Hoffmann-La Roche | RHHBY | 1 | PHASE3 | Baloxavir Marboxil |
| Merck & Co., Inc. | MRK | 2 | PHASE1 | V118C |
| AstraZeneca PLC | AZN | 1 | PHASE1 | AZD7760 |
| BioNTech SE Sponsored ADR | BNTX | 1 | PHASE1 | BNT163 |
| 60 Degrees Pharmaceuticals, Inc. | SXTP | 1 | PHASE2 | Tafenoquine |
| Tarsus Pharmaceuticals, Inc. | TARS | 1 | PHASE2 | TP-05 |
| Moderna, Inc. | MRNA | 1 | PHASE2 | mRNA-1982 |
| AN2 Therapeutics, Inc. | ANTX | 1 | PHASE2 | Epetraborole |
| Emergent BioSolutions Inc. | EBS | 4 | - | AIGIV/kg |
| Phathom Pharmaceuticals, Inc. | PHAT | 1 | - | Vonoprazan |
Efavirenz is used to treat HIV Infections. It is an antiretroviral small molecule studied as part of combination regimens in HIV-infected patients, including treatment-experienced patients and those receiving rifampin for active tuberculosis. The clinical trials listed for Efavirenz enrolled adults and adolescents with HIV Infections.
Efavirenz is developed by Gilead Sciences, Inc., which trades under the ticker GILD. The company is listed as the developer of the Efavirenz program in HIV Infections.
Efavirenz is in Phase 2 clinical development for HIV Infections. Three Phase 2 trials are registered, of which two are completed and none are currently active. The completed studies together enrolled 205 participants.
Registered Efavirenz trials include NCT00822315, which studied two raltegravir doses in naive HIV-1-infected patients receiving rifampin for active tuberculosis, and NCT00002419 and NCT00002234, which evaluated anti-HIV drug combinations including Efavirenz in HIV-infected patients. All three Phase 2 trials are completed.
Yes, Efavirenz is also known as Efavirenz (EFV), so EFV is simply the abbreviated name for the same drug. Searches for either name refer to the same small molecule developed by Gilead Sciences for HIV Infections.
The Efavirenz Phase 2 trials were randomized and active controlled, and none were double blind. Enrollment ranged from 25 to 155 participants. The studies took place in the United States, Brazil, and France, and enrolled patients aged 13 years and older, with no healthy volunteers.